Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Inflammatory bowel disease stories

Oct 22, 2026

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00
Aug 28, 2026

FDA Approves Stelara for Pediatric Ulcerative Colitis

The FDA approved ustekinumab (Stelara) on August 28, 2026 for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older, making it the first non-TNF biologic approved for pediatric IBD.

Aug 28, 2026·1 source
00
Apr 13, 2026

Spyre Therapeutics IBD Drug Shows Promise in Early-Stage Trial

Spyre Therapeutics' inflammatory bowel disease therapy succeeded in its first major clinical testing, setting up competition with several large pharmaceutical companies in the IBD space.

Apr 13, 2026·1 source
00

Top claims

  • ▪Citi analyst Geoffrey Meacham stated that Gilead Sciences' $1.275 billion upfront payment was notable given that HCXT-2001 remains in Phase 1 testing without published clinical data
  • ▪Gilead Sciences Chief Executive Officer Daniel O'Day stated that Gilead Sciences' strategy in inflammation focuses on earlier-stage business deals to drive long-term pipeline growth
  • ▪In Gilead Sciences' Phase 2 trial for ulcerative colitis, 31% of patients receiving the highest dose of emvistegrast achieved clinical remission at 12 weeks compared to 8% in the placebo group

Topics

Mergers and acquisitionsDigestive diseasesAutoimmune disease treatmentsBiotech innovationPharmaceutical IndustryImmunologyDrug developmentMergers & acquisitions (M&A)Drug Approval and Clinical TrialsBiologic therapiesChild healthDrug Policy, Pricing & ApprovalAdolescent healthFDA drug approvalInflammation reduction & immune effects

Related entities

StelaraPediatric careJanssen BiotechFDA drug approval